Race-Free Kidney Equation Changes Status of Millions in US Race-Free Kidney Equation Changes Status of Millions in US
If a new race-free equation for assessing chronic kidney disease is widely adopted in the US, this will potentially impact medication dosing, insurance coverage, and kidney transplant eligibility.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 23, 2023 Category: Intensive Care Tags: Nephrology News Source Type: news
Enlarged Heart Tied to Worse Chronic Kidney Disease Outcomes
WEDNESDAY, Feb. 22, 2023 -- The cardiothoracic ratio (CTR) has real-world prognostic value for chronic kidney disease (CKD), according to a study published online Feb. 7 in Communications Medicine.
Che-Yi Chou, from Asia University Hospital in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 22, 2023 Category: Pharmaceuticals Source Type: news
Higher Insulin Resistance Predicts Incident T2D, CKD Higher Insulin Resistance Predicts Incident T2D, CKD
Prospectively collected data from 4314 South Korean adults showed that people with higher levels of insulin resistance have the greatest rate of incident type 2 diabetes and chronic kidney disease.First Look (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 22, 2023 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Kerendia ™ (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
The European Commission granted approval for a label extension for Kerendia™ (finerenone) in the European Union (EU) to include results on cardiovascular (CV) outcomes from the Phase III FIGARO-DKD study. The study demonstrated that Kerendia reduced the risk of CV events in a broad population of patients with stages 1-4 CKD and T2D. (Source: World Pharma News)
Source: World Pharma News - February 13, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Risk Factors for Pediatric CKD Progression Identified
FRIDAY, Feb. 3, 2023 -- Chronic kidney disease (CKD) progression in children is associated with specific clinical risk factors, according to a study published online Jan. 24 in Journal of the American Society for Nephrology.
Carolina A. Gluck, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 3, 2023 Category: Pharmaceuticals Source Type: news
Chronic kidney disease puzzle highlighted at Costa Rica workshop
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2019/5/science-highlights/kidney-disease/thumb868606.jpg?itok=vlDiWF28" /><br /><p>Researchers from around the world shared insights into chronic kidney disease of unknown origin in agricultural communities.</p>
(read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news
Chronic kidney disease in agricultural workers tackled at workshop
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2018/8/science-highlights/kidney_disease/thumb851251.jpg?itok=tcWrzhQt" /><br /><p>Chronic kidney disease of unknown origin was the focus of National Institute of Diabetes and Digestive and Kidney Diseases and NIEHS workshop.</p>
(read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news
First Oral Treatment for CKD Anemia OK'd for Patients on Dialysis
(MedPage Today) -- The FDA approved the first oral agent for chronic kidney disease (CKD)-related anemia for adults on dialysis, the agency announced late on Wednesday.
Daprodustat (Jesduvroq) is a once-daily tablet specifically indicated for... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - February 2, 2023 Category: Urology & Nephrology Source Type: news
FDA Approves Daprodustat, First Oral Anemia Treatment FDA Approves Daprodustat, First Oral Anemia Treatment
The US Food and Drug Administration has approved daprodustat as oral treatment for anemia in patients with chronic kidney disease and on dialysis, but not for patients who are not on dialysis.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 2, 2023 Category: Drugs & Pharmacology Tags: Nephrology News Alert Source Type: news
FDA Approves First Oral Agent For Anemia in Kidney Dialysis Patients FDA Approves First Oral Agent For Anemia in Kidney Dialysis Patients
The US Food and Drug Administration has approved daprodustat as oral treatment for anemia in patients with chronic kidney disease and on dialysis, but not for patients who are not on dialysis.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 2, 2023 Category: Intensive Care Tags: Nephrology News Alert Source Type: news
FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis
The FDA approved the first oral treatment for anemia caused by chronic kidney disease for adults who have been receiving dialysis for at least four months. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 1, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Jesduvroq (daprodustat) for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis
February 01, 2023 -- Today, the U.S. Food and Drug Administration approved Jesduvroq tablets (daprodustat) as the first oral treatment for anemia (decreased number of red blood cells) caused by chronic kidney disease for adults who have been... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 1, 2023 Category: Drugs & Pharmacology Source Type: news
Model With Lifestyle, Health Behavior Information Predicts CKD
TUESDAY, Jan. 31, 2023 -- Self-reported lifestyle and health behavior information can predict incident chronic kidney disease (CKD), according to a study published in the January issue of the Clinical Journal of the American Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2023 Category: Pharmaceuticals Source Type: news
Jardiance Under Review for CKD; Frailty in Obesity; DIY Semaglutide?
(MedPage Today) -- The FDA is reviewing a potential new indication for empagliflozin (Jardiance) for risk reduction of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD) based on the EMPA-KIDNEY phase... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 24, 2023 Category: Endocrinology Source Type: news
Higher Seafood n-3 PUFA Levels Tied to Lower Risk for Incident CKD
MONDAY, Jan. 23, 2023 -- The risk for incident chronic kidney disease (CKD) is lower with higher seafood-derived omega 3 polyunsaturated fatty acid (n-3 PUFA) levels, according to research published online Dec. 18 in The BMJ.
Kwok Leung Ong, Ph.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 23, 2023 Category: Pharmaceuticals Source Type: news
